Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis
Authors:
- 1 June 2021
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (6) , e192-e208
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaNew England Journal of Medicine, 2009
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005
- A Single Measure of FEV 1 Is Associated With Risk of Asthma Attacks in Long-term Follow-upChest, 2004
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000